As­traZeneca mines an­oth­er $6B ADC from Dai­ichi Sankyo, with block­buster am­bi­tions to ‘re­de­fine treat­ment stan­dards’

Pas­cal So­ri­ot isn’t let­ting the all-con­sum­ing R&D and man­u­fac­tur­ing work on a Covid-19 vac­cine slow down his hunt for As­traZeneca’s next block­buster can­cer drugs.

The lat­est deal with Dai­ichi Sankyo con­sists of $1 bil­lion in up­front cash pay­ment spread over 2 years: $350 mil­lion up­on com­ple­tion, and $325 mil­lion each at the 12-month and 24-month mark. Reg­u­la­to­ry mile­stones add up to an­oth­er $1 bil­lion while sales-re­lat­ed fees tot up to $4 bil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER